INDICATIONS

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

THE NEED FOR REBLOZYL: MECHANISM OF ACTION

Impaired erythroid maturation graphic Impaired erythroid maturation graphic

EARLY-STAGE ERYTHROPOIESIS

Endogenous erythropoietin regulates proliferation4

LATE-STAGE ERYTHROPOIESIS

Select TGF-β superfamily ligands help regulate maturation TGF-β superfamily signaling through Smad2/3 is abnormally high in diseases characterized by ineffective erythropoiesis, which leads to impaired erythroid maturation of RBCs5-7

For illustrative purposes only.

BFU-E=burst-forming unit erythroid; CFU-E=colony-forming unit erythroid; HSC=hematopoietic stem cell; RBC=red blood cell;
TGF-beta=transforming growth factor beta.

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

REBLOZYL® enhanced erythroid maturation graphic REBLOZYL® enhanced erythroid maturation graphic

EARLY-STAGE ERYTHROPOIESIS

Endogenous erythropoietin regulates proliferation4

LATE-STAGE ERYTHROPOIESIS

REBLOZYL regulates erythroid maturation REBLOZYL binds several TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7

For illustrative purposes only.

In preclinical models, REBLOZYL improved Hgb levels, RBC morphology, and other hematology parameters* associated with ineffective erythropoiesis1,6

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin.

THE NEED FOR REBLOZYL: MECHANISM OF ACTION

Impaired erythroid maturation graphic Impaired erythroid maturation graphic

EARLY-STAGE ERYTHROPOIESIS

Endogenous erythropoietin regulates proliferation4

LATE-STAGE ERYTHROPOIESIS

Select TGF-β superfamily ligands help regulate maturation TGF-β superfamily signaling through Smad2/3 is abnormally high in diseases characterized by ineffective erythropoiesis, which leads to impaired erythroid maturation of RBCs5-7

For illustrative purposes only.

BFU-E=burst-forming unit erythroid; CFU-E=colony-forming unit erythroid; HSC=hematopoietic stem cell; RBC=red blood cell;
TGF-beta=transforming growth factor beta.

REBLOZYL restores erythropoiesis by increasing the number and improving the quality of mature RBCs as observed in preclinical studies1

REBLOZYL® enhanced erythroid maturation graphic REBLOZYL® enhanced erythroid maturation graphic

EARLY-STAGE ERYTHROPOIESIS

Endogenous erythropoietin regulates proliferation4

LATE-STAGE ERYTHROPOIESIS

REBLOZYL regulates erythroid maturation REBLOZYL binds several TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling and increasing the number of mature RBCs1,6,7

For illustrative purposes only.

In preclinical models, REBLOZYL improved Hgb levels, RBC morphology, and other hematology parameters* associated with ineffective erythropoiesis1,6

*Other hematology parameters include reducing oxidative stress in erythrocytes, reducing accumulation of α-globin aggregates in erythrocyte membranes, and improving RBC life span.

Hgb=hemoglobin.

References: 1. REBLOZYL [US Prescribing Information]. Summit, NJ: Celgene Corporation; 2023. 2. Liang R, Ghaffari S. Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease. Br J Haematol. 2016;174(5):661-673. 3. Ponka P, Koury MJ, Sheftel AD. Erythropoiesis, hemoglobin synthesis, and erythroid mitochondrial iron homeostasis. In: Ferreira GC, ed. Handbook of Porphyrin Science: With Applications to Chemistry, Physics, Materials Science, Engineering, Biology and Medicine. Vol 27. Singapore: World Scientific Publishing Co.; 2014. 4. Lodish H, Flygare J, Chou S. From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones. IUBMB Life. 2010;62(7):492-496. 5. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96(6):2022-2036. 6. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414. 7. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.